{"id":597759,"date":"2022-04-27T17:04:01","date_gmt":"2022-04-27T17:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=597759"},"modified":"2022-04-27T17:04:01","modified_gmt":"2022-04-27T17:04:01","slug":"diabetic-retinopathy-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-roche-kubota-vision-novartis-adverum-biotechnologies-kalvista-pharma-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-retinopathy-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-roche-kubota-vision-novartis-adverum-biotechnologies-kalvista-pharma-and-others_597759.html","title":{"rendered":"Diabetic Retinopathy Market is Projected to Boost at a Moderate Growth Rate by 2032 &#8211; DelveInsight | Key Companies- Roche, Kubota Vision, Novartis, Adverum Biotechnologies, KalVista Pharma, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Diabetic Retinopathy Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies- Roche, Kubota Vision, Novartis, Adverum Biotechnologies, KalVista Pharma, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1588078163.png\" alt=\"Diabetic Retinopathy Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies- Roche, Kubota Vision, Novartis, Adverum Biotechnologies, KalVista Pharma, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Retinopathy Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Diabetic Retinopathy market report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Diabetic Retinopathy Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/f8c6f3da0f4b5dd92b59af72397c66b4.jpg\" alt=\"Diabetic Retinopathy Market\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Retinopathy: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-aged people. It is identified in a third of people with diabetes and is associated with an increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. <\/em><\/p>\n<p style=\"text-align: justify;\"><em>In the USA, an estimated <strong>40% (8% for vision-threatening retinopathy)<\/strong> of people with type 2 diabetes and <strong>86% (42%)<\/strong> with type 1 diabetes have diabetic retinopathy.<\/em><\/p>\n<p style=\"text-align: justify;\"><em>Diabetic retinopathy in the initial stages is asymptomatic. However, as diabetic retinopathy gets worse with time, one will notice symptoms such as: seeing an increasing number of floaters, having blurry vision, having a vision that sometimes changes from blurry to clear, seeing blank or dark areas in your field of vision, having poor night vision, and noticing colours appear faded or washed out, losing vision.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Diabetic Retinopathy Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>The total diagnosed prevalent population of Diabetic Retinopathy (DR) in the 7MM was estimated to be <strong>8,033,000+ cases<\/strong> in 2020.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>Among the European countries, Germany had the highest population of Diabetic Retinopathy with 2,167,200+ cases, followed by Italy which had<strong> 1,485,600+<\/strong> cases in 2020.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em>&nbsp;Among the EU5 countries, France had the lowest prevalent population with<strong> 575,500+ cases<\/strong> in 2020.<\/em><\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><em><em><em>The prevalent population of Diabetic Retinopathy in Japan was <strong>1,903,500+ cases<\/strong> in 2020.<\/em><\/em><\/em><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Diabetic Retinopathy Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><em>As per DelveInsight, the <strong>Diabetic Retinopathy Market<\/strong> is expected to show positive growth, mainly attributed by increased prevalence and the expected launch of novel therapies, such as <strong>Faricimab (Roche)<\/strong>,<strong>Brolucizumab (Novartis Pharmaceuticals), <\/strong>among others.<br \/><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Diabetic Retinopathy market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives complete detail of the <strong>Diabetic Retinopathy market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Retinopathy Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section provides insights into the historical and current <strong>Diabetic Retinopathy epidemiology trends <\/strong>in the&nbsp;seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool, future trends, and assumptions undertaken.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Retinopathy Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Prevalent cases of Diabetic Retinopathy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gender-specific cases of Diabetic Retinopathy<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Age-specific cases of Diabetic Retinopathy<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Retinopathy Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Diabetic Retinopathy market<\/strong> or expected to get launched during the study period. The analysis covers Diabetic Retinopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers the <strong>Diabetic Retinopathy Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/diabetic-retinopathy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Retinopathy Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Diabetic Retinopathy Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Roche<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kubota Vision&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Novartis Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Adverum Biotechnologies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KalVista Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Diabetic Retinopathy Therapies covered in the report include<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Brolucizumabt<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Faricimab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ADVM-022<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KVD001<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Emixustat Hydrochloride<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/diabetic-retinopathy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Diabetic Retinopathy Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Diabetic Retinopathy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Diabetic Retinopathy Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Diabetic Retinopathy Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Diabetic Retinopathy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Diabetic Retinopathy Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Diabetic Retinopathy Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Diabetic Retinopathy Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Diabetic Retinopathy Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Diabetic Retinopathy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Diabetic Retinopathy Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Diabetic Retinopathy Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Diabetic Retinopathy Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Diabetic Retinopathy Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Diabetic Retinopathy Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Diabetic Retinopathy Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-retinopathy-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/diabetic-retinopathy-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bacterial-conjunctivitis-market\">Bacterial Conjunctivitis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<strong>Bacterial Conjunctivitis Market<\/strong>&rdquo; research report delivers an in-depth understanding of the historical and forecasted epidemiology, market size, share, trends as well as the emerging therapies and the key companies operating in the Bacterial Conjunctivitis therapeutics landscape.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75613.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=diabetic-retinopathy-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-roche-kubota-vision-novartis-adverum-biotechnologies-kalvista-pharma-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=diabetic-retinopathy-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-roche-kubota-vision-novartis-adverum-biotechnologies-kalvista-pharma-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Diabetic Retinopathy Market size, share, and trends in the seven &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/diabetic-retinopathy-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-roche-kubota-vision-novartis-adverum-biotechnologies-kalvista-pharma-and-others_597759.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,405,417,406],"tags":[],"class_list":["post-597759","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=597759"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/597759\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=597759"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=597759"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=597759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}